SCHEMBL7952257

SCHEMBL7952257

CCCCCCC(Sc1ccccc1Nc1ccncc1)C(=O)NO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
ADAM17 P78536 1/20 0.43
PPARG P37231 5/20 0.41
PPARA Q07869 5/20 0.41
HDAC8 Q9BY41 7/20 0.41
HDAC3 O15379 5/20 0.41
HDAC6 Q9UBN7 5/20 0.41
HDAC1 Q13547 4/20 0.41
HDAC2 Q92769 4/20 0.41
PTGES O14684 4/20 0.39
ALOX5 P09917 3/20 0.39
HDAC4 P56524 2/20 0.39
HDAC7 Q8WUI4 2/20 0.39
HDAC10 Q969S8 2/20 0.39
HDAC11 Q96DB2 2/20 0.39
HDAC9 Q9UKV0 2/20 0.39
HDAC5 Q9UQL6 2/20 0.39
CETP P11597 1/20 0.38
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6930731 0.82 MMP9 (0.56) MMP9MMP13ADAM17PPARGPPARA
SCHEMBL7691773 0.77 MMP9 (0.49) MMP9MMP13ADAM17HDAC8HDAC3
SCHEMBL7616072 0.75 MMP9 (0.51) MMP9MMP13ADAM17PPARGPPARA
SCHEMBL7393115 0.74 MMP9 (0.51) MMP9MMP13ADAM17PPARGPPARA
SCHEMBL6932495 0.73 MMP9 (0.55) MMP9MMP13ADAM17PPARGPPARA
SCHEMBL7511090 0.71 MMP9 (0.48) MMP9MMP13ADAM17PPARGHDAC8
SCHEMBL7509127 0.71 MMP9 (0.44) MMP9MMP13ADAM17PPARGPPARA
SCHEMBL6931609 0.69 MMP9 (0.61) MMP9MMP13ADAM17PPARGPPARA
SCHEMBL7317662 0.69 MMP9 (0.55) MMP9MMP13ADAM17PPARGPPARA
SCHEMBL6931550 0.68 MMP9 (0.47) MMP9MMP13ADAM17PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6331563-B1 LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE WYETH HOLDINGS CORPORATION 2001-12-18 US disclosed